PGN-EDO53 NHP Exon Skipping, PGN-EDO45 and PGN-EDO44 Exon Skipping in Wild-Type Human Myoblasts High levels of exon skipping were observed for PGN-EDO53 in NHPs, and for PGN-EDO45 and PGN-EDO44 in ...
PT Perusahaan Gas Negara Tbk (PGN) sebagai Subholding Gas Pertamina menegaskan komitmennya dalam memberikan layanan energi ...
BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming ...
"CNG menjadi solusi, sehingga semakin banyak masyarakat dapat merasakan manfaat energi yang efisien, praktis dan ramah ...
PepGen shifts focus to PGN-EDODM1 for Myotonic Dystrophy Type 1 after discontinuing PGN-EDO51 for Duchenne Muscular Dystrophy ...
PepGen Inc. (($PEPG)) announced an update on their ongoing clinical study. Study Overview: PepGen Inc. is conducting a Phase 2 clinical study ...
Lebih jauh, melalui dukungan PGN Gagas, pasokan gas bumi disalurkan secara rutin untuk memenuhi kebutuhan energi memasak di ...
Kontan on MSN
PGN Gagas 3.000 m³ Gas Bumi per Bulan untuk SPPG MBG
Untuk memastikan kelancaran operasional, PGN Gagas menyalurkan sekitar 2.000–3.000 m³ gas bumi per bulan menggunakan ...
Approaches for controlling inflammatory responses and reducing the mortality rate of septic patients remain clinically ineffective; new drugs need to be identified that can induce anti-inflammatory ...
- EDO platform observed to drive 25-fold higher level of oligonucleotide delivery to myotube nuclei compared to “naked” oligonucleotide - - EDO technology enabled delivery of therapeutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback